Introduction
============

Leiomyomas, also known as fibroids, are the most frequent benign uterine tumors to develop during a woman's reproductive years; occurrence tends to regress after menopause.[@b1-ijwh-5-689] Malign transformation of uterine leiomyoma (UL) seems to be a very rare event,[@b2-ijwh-5-689] but they are symptomatic in 20%--30% of cases and are the main reason for approximately one-third of all hysterectomies in developed countries.[@b3-ijwh-5-689],[@b4-ijwh-5-689] Symptoms related to UL are menstrual disorders, mainly menorrhagia, pelvic pain, and infertility, which can adversely affect pregnancy outcomes.[@b5-ijwh-5-689],[@b6-ijwh-5-689] UL disproportionately affects Black women.[@b4-ijwh-5-689],[@b7-ijwh-5-689],[@b8-ijwh-5-689] The etiology of UL is unknown, but it can be influenced by genetic liability,[@b9-ijwh-5-689] hormonal environment,[@b10-ijwh-5-689],[@b11-ijwh-5-689] and local tissue mediators.[@b10-ijwh-5-689],[@b12-ijwh-5-689] Definitive prevalence of UL in the general female population is also unknown, but differs by ethnicity, age, and method used for diagnosis.[@b13-ijwh-5-689] In clinical practice, transvaginal ultrasonography (TVS) is the most widespread method for evaluating UL, with an estimated accuracy of 87%--92%.[@b14-ijwh-5-689]--[@b16-ijwh-5-689]

The objective of this study was to determine the prevalence of UL, diagnosed by TVS, at a private health care setting located in the central eastern part of Portugal, and to explore the demographic and clinical factors related to diagnosis and symptomatology.

Materials and methods
=====================

The study retrospectively analyzed the medical files of all female patients who consecutively attended a gynecological consultation at a private health care setting located in Covilhã, Portugal, from December 2--31, 2010. Excluded from the study were virgins, patients who had previously undergone a hysterectomy, or those pregnant at the time of the consultation. All included patients were Caucasian, except three, who were African.

The same gynecologist (JAF), who has more than 20 years of gynecological experience and competence in the practice of gynecologic ultrasound, attended all patients.

Policies of the private clinic include recording of demographic and clinical data from every patient in a standard digital database. In all cases, an office TVS was offered to the patient. The sonographic equipment used was a Nemio 17 (SSA-550A) with a PVM-651VT 6 MHz endovaginal probe (Toshiba Corporation, Tokyo, Japan).

For the anonymous use of data from patient files, written consent was obtained from the clinical director of the private health care clinic. LSB and DGT analyzed the files of 624 patients who met the inclusion criteria, and from each file they retrieved age, weight, height, age at menarche, number of pregnancies and deliveries, marital status, menstrual cycles characteristics, and contraceptive method at time of consultation. The presence, number, and largest dimension of the ULs were retrieved from TVS records. For analysis, the data recorded at the first consultation in 2010 were considered. Ultrasound records were analyzed for the presence or absence of UL, their number, location and largest dimension.

The data were organized and analyzed in Statistical Package for the Social Sciences® software (\[SPSS\] v 20.0 for Windows; IBM Corporation, Armonk, NY, USA), by SMN. Univariate analysis and multivariate logistic regression analysis were performed. In all cases, *P* \< 0.05 was considered significant.

Results
=======

Using TVS, UL was diagnosed in 161 (25.8%) of those 624 cases included in the study. From those 161 patients with an ultrasound-based diagnosis of UL, 99 (61.5%) had previous knowledge of the disease. In three patients, resectoscopic myomectomy was proposed for treating symptomatic sub-mucous leiomyoma.

The demographic characteristics of the studied population are shown in [Table 1](#t1-ijwh-5-689){ref-type="table"}. The mean age was 39.6 years; 66.2% of the women were married; 68.2% reported having had at least one pregnancy and 64.2% at least one delivery; 31.6% were asymptomatic. UL was diagnosed by ultrasound in 11.0% of all women aged 20 to 39 years old, in 45.4% of all women aged 40 to 59 years, and in 19.5% of all women aged 60 years or more. Metrorrhagia and menorrhagia were the most usual presenting symptoms, and were recorded in 11.3% of all cases and in 22.3% of all women with an ultrasound diagnosis of UL.

The uterus was explored with clinical bimanual palpation and TVS. Results of clinical and ultrasound exploration of the uterus are shown in [Table 2](#t2-ijwh-5-689){ref-type="table"}. The overall prevalence of UL was 17.0% by bimanual palpation and 25.8% by TVS. ULs larger than 3.0 cm were identified through ultrasound imaging in 24.2% of the cases.

In order to uncover significant demographic and clinical differences between women with and without ultrasound diagnosis of UL, a univariate analysis was performed ([Table 3](#t3-ijwh-5-689){ref-type="table"}). Significant factors associated with an ultrasound-based diagnosis of UL were the following: 40 to 59 years of age; married; excessive body weight (obese); prior pregnancy or delivery; non-use of the combined pill for contraception; and symptoms of menorrhagia. However, after adjustment by multivariate logistic regression analysis, age 40 to 59 years remained the single demographic and clinical factor found to be statistically associated with ultrasonographic diagnosis of UL.

Menorrhagia, metrorrhagia, and pelvic pain were the most frequent presenting symptoms. When menorrhagia was the presenting symptom, an ultrasound imaging diagnosis of UL was made in 73.3% of cases ([Table 3](#t3-ijwh-5-689){ref-type="table"}). Plotting a univariate analysis, metrorrhagia and menorrhagia as presenting symptoms were significantly related to the TVS diagnosis of multiple ULs, but not with the largest UL dimension ([Tables 4](#t4-ijwh-5-689){ref-type="table"} and [5](#t5-ijwh-5-689){ref-type="table"}). Although lacking statistical significance, patients diagnosed with smaller ULs seemed to be more symptomatic ([Table 5](#t5-ijwh-5-689){ref-type="table"}).

Discussion
==========

The real prevalence of UL in the general population is unknown. UL prevalence has been evaluated by different methods, such as population surveys,[@b17-ijwh-5-689] pathologic study of surgical specimens of hysterectomy,[@b18-ijwh-5-689] postmortem of women who died without gynecological diseases,[@b19-ijwh-5-689] and pelvic ultrasonography,[@b13-ijwh-5-689],[@b20-ijwh-5-689],[@b21-ijwh-5-689] with, as expected, different results.

Kratochwil et al[@b22-ijwh-5-689] introduced ultrasound imaging of feminine pelvic organs in 1972. In 1980, Muram et al[@b23-ijwh-5-689] defined criteria for UL identification with TVS as a relatively spherical mass that is echogenically different from the surrounding myometrium. Since then, TVS has become the most noninvasive, lowest-cost, and widespread method for evaluation of uterine pathology, with highly accurate performance.[@b14-ijwh-5-689]--[@b16-ijwh-5-689] The main disadvantage of ultrasound is that it is an operator-and device-dependent technique.[@b24-ijwh-5-689] In order to improve UL diagnosis accuracy, saline contrast sonohysterography and three-dimensional ultrasound have been proposed, although with conflicting results.[@b24-ijwh-5-689],[@b25-ijwh-5-689] Nowadays, two-dimensional pelvic ultrasonography remains the best method for routine detection of ULs.[@b24-ijwh-5-689],[@b25-ijwh-5-689] Ultrasonography has been shown to be an insufficient method of myoma mapping, and magnetic resonance imaging should preferred for surgical therapy planning.[@b25-ijwh-5-689]

In the present study, we found a 25.8% overall prevalence of UL, with the highest prevalence (45.4%) in women aged 39--50 years, which is in accordance with previous ultrasound-based studies.[@b13-ijwh-5-689],[@b20-ijwh-5-689],[@b26-ijwh-5-689] Multiple ULs were present in 50.1% of cases, which is lower than that reported in surgical specimens by Cramer and Patel (84%).[@b18-ijwh-5-689] In contrast to Cramer and Patel's findings, only 49.1% patients had a UL larger than 20 mm. A previous diagnosis of UL had been made in 99 (61.5%) patients, who were in watchful waiting management, which has been considered as a safe management option for asymptomatic UL.[@b27-ijwh-5-689],[@b28-ijwh-5-689] Except in three cases submitted to resectoscopy for treatment of symptomatic submucous myomas, the main component of the leiomyomas was intramural. A purely intramural myoma represents a temporary status, and its growth is dependent on the existing hormonal conditions of the woman.[@b29-ijwh-5-689]

Most of the knowledge about demographic and clinical risk factors for UL is based on results of large populations survey studies. Risk factors such as age, ethnicity, education, hormonal factors, diet, physical exercise, oral contraceptives use, childbirth, smoking and tissue injury has been reported, with conflicting results. In accordance with other ultrasound-based studies,[@b13-ijwh-5-689],[@b20-ijwh-5-689],[@b26-ijwh-5-689] after multivariate statistical analysis, we don't found any demographic or clinical risk factor for UL, with exception of age.

The most common symptom of UL is abnormal uterine bleeding, especially menorrhagia.[@b5-ijwh-5-689] The mechanism of leiomyoma-associated menorrhagia is unknown, but submucous localization, vascular defects, and impaired endometrial hemostasis have been suggested as possible explanations.[@b30-ijwh-5-689],[@b31-ijwh-5-689] Even small ULs without distortion of the endometrial cavity can alter myometrial vascularization and contractibility. A meta-analysis conducted by Benecke et al[@b32-ijwh-5-689] reported that intramural ULs may have a negative impact on fertility. In our series, menorrhagia was significantly associated with multiplicity of ULs, but not with the volume of the largest one, suggesting the importance of factors other than those associated with distortion of the myometrium and endometrial cavity. Extracellular matrix that embed UL cells influence both normal myometrial and UL cells, promoting proliferative activity and decreasing apoptosis.[@b33-ijwh-5-689],[@b34-ijwh-5-689] Previous ultrasound-based studies[@b20-ijwh-5-689]--[@b35-ijwh-5-689] have reported that the presence, number, and volume of leiomyomas are unrelated to abnormalities in the menstrual cycle. Other studies,[@b36-ijwh-5-689],[@b37-ijwh-5-689] but not all,[@b38-ijwh-5-689] suggest that menstrual symptoms are related to tissue layer location in the uterine wall and with the axial position of leiomyomas. In our study, multiplicity of ULs was significantly related to abnormal uterine bleeding (menorrhagia and metrorrhagia) as a presenting symptom.

Currently, most women with menstrual disorders and multiple ULs are scheduled for medical therapy followed by hysterectomy or myomectomy.[@b39-ijwh-5-689] Hysterectomy seems a good option when childbearing wishes have been fulfilled;[@b39-ijwh-5-689] but it is not devoid of risks, morbidity and mortality as for any surgical procedure. Myomectomy is indicated for those women who wish to retain their fertility.[@b39-ijwh-5-689] The major disadvantage of surgical myomectomy is leiomyoma recurrence. In next 5 years, more than one-third of that women submitted to myomectomy will need additional surgical intervention for treatment of newly developed ULs.[@b40-ijwh-5-689] Minimally invasive procedures, such as laparoscopic myolysis, uterine artery embolization, uterine fibroid embolization, and magnetic resonance-guided focused ultrasound, as standard practice for treatment of symptomatic multiple ULs are currently limited.[@b41-ijwh-5-689] It seems obvious that new treatments better than surgical approaches are needed for the management of symptomatic UL.

In recent years, intense scientific research has brought new insights on UL biology. The development of ULs has been shown to be dependent of sex steroids, especially progesterone,[@b42-ijwh-5-689],[@b43-ijwh-5-689] and many leiomyoma-related growth factors have been identified, including epidermal growth factor, platelet-derived growth factor, transforming growth factor beta, insulin-like growth factor, activin, and myostatin. We speculate that, in patients with multiple ULs and menstrual disorders, each UL can produce different kinds of growth factors or other biological mediators that may have additive negative effects on the myometrial and endometrial environment.

Discovery of selective progesterone receptor modulators (SPRMs) has provided a new paradigm for treatment of symptomatic UL. Antiproliferative, growth factors down-regulation, and proapoptotic actions of SPRMs had been reported in vitro studies over cultured leiomyoma cells.[@b43-ijwh-5-689] Randomized, placebo-controlled clinical trials have demonstrated that the SPRM ulipristal can suppress menstrual bleeding, restore normal levels of hemoglobin, reduce UL volume, and improve leiomyoma-related symptoms.[@b44-ijwh-5-689],[@b45-ijwh-5-689]

The main objective of symptomatic UL treatment is to regress symptomatology, because expectant management is suitable for most asymptomatic leiomyomas.[@b27-ijwh-5-689],[@b28-ijwh-5-689] It is expected that new therapies for the treatment of UL-associated symptomatology will be developed, based on the growing knowledge of functional aspects and regulatory mechanisms of leiomyoma biology and uterine homeostasis.

Conclusion
==========

To our knowledge, this is the first population study conducted in Portugal to assess the prevalence and demographic and clinical factors associated with the diagnosis of UL by ultrasound. In our Portuguese population, the prevalence of uterine leiomyoma increases with age, and was similar to that reported in literature for White women.

Menorrhagia and metrorrhagia were the more distressing symptoms, especially in patients with multiple ULs diagnosed by TVS. In patients with abnormal uterine bleeding, special attention should be taken to search for multiple leiomyomas during pelvic ultrasound examination.

Further studies are needed to assess the biology and symptomatic impact of multiple versus single ULs, in order to find more efficient therapeutic approaches.
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###### 

Demographic characteristics (624 cases)

  Demographic data                  Total (624 cases)   Leiomyoma (161 cases)            
  --------------------------------- ------------------- ----------------------- -------- ------
  Age (years)                                                                            
   Range                            15--77                                      21--71   
   Median                           39.62                                       46.65    
   19 or less                       12                  1.9                     0        0
   20--39                           309                 49.5                    34       21.1
   40--59                           262                 42.0                    119      73.9
   60 or more                       41                  6.6                     8        5.0
  Education                                                                              
   High school or less              394                 63.1                    108      67.1
   College or more                  230                 36.9                    53       32.9
  Marital status                                                                         
   Married                          413                 66.2                    127      78.9
   Single                           155                 24.8                    13       8.0
   Divorced                         33                  5.3                     12       7.5
   Widowed                          23                  3.7                     9        5.6
  Body mass index                                                                        
   18.4 or less                     20                  3.2                     3        1.9
   18.5--24.9                       371                 59.5                    76       47.2
   25--29.9                         169                 27.1                    56       34.8
   30 or more                       64                  10.3                    26       16.1
  Age at menarch (years)                                                                 
   12 or less                       312                 50.0                    81       50.0
   13 or more                       312                 50.0                    80       50.0
  Number of pregnancies                                                                  
   0                                198                 31.7                    21       13.0
   1                                156                 25.0                    54       33.5
   2                                163                 26.1                    50       31.1
   3 or more                        107                 17.1                    36       22.4
  Number of deliveries                                                                   
   0                                223                 35.7                    28       17.4
   1                                163                 26.1                    60       37.3
   2 or more                        238                 38.1                    73       45.3
  Miscarriage                                                                            
   Total                            426                                         140      
   No                               334                 78.4                    105      75.0
   Yes                              92                  21.6                    35       25.0
  Cesarean section                                                                       
   Total                            401                                         133      
   No one                           321                 80.0                    109      81.9
   One or more                      80                  20.0                    24       18.1
  Contraception                                                                          
   Combined pill                    207                 33.2                    29       18.0
   Progestin pill or hormonal IUD   54                  8.7                     16       9.9
   Other                            363                 58.1                    116      72.1
  Presenting symptom                                                                     
   Screening (asymptomatic)         197                 31.6                    47       29.2
   Metrorrhagia                     67                  10.7                    25       15.5
   Menorrhagia                      15                  2.4                     11       6.8
   Pelvic pain                      61                  9.8                     20       12.4
   Vulvar symptoms                  66                  9.6                     13       8.1
   Breast symptoms                  47                  7.5                     12       7.5
   Leukorrhea                       36                  5.8                     6        3.7
   Contraception counseling         31                  5.0                     5        3.1
   Infertility counseling           21                  3.4                     0        0
   Other                            89                  9.3                     22       13.7

**Abbreviation:** IUD, intrauterine device.

###### 

Clinical and ultrasound uterus exploration data (624 cases)

  Clinical and ultrasound data                               N     \%
  ---------------------------------------------------------- ----- ------
  Uterine size at gynecological examination                        
   Normal size                                               518   83.0
   Uterine enlargement                                       106   17.0
  Uterine leiomyoma at ultrasound                                  
   Yes                                                       161   25.8
   No                                                        463   74.2
  Number of leiomyomas at ultrasound (161 women)                   
   Single                                                    80    49.7
   Multiple                                                  81    50.3
  Dimension of largest leiomyoma at ultrasound (161 women)         
   \<20 mm                                                   79    49.1
   20--29 mm                                                 43    26.7
   30--39 mm                                                 18    11.2
   40--49 mm                                                 11    6.8
   \>50 mm                                                   10    6.2
  Previous patient knowledge about leiomyoma (161 women)           
   Yes                                                       99    61.5
   No                                                        62    38.5

###### 

Univariate analysis of demographic and clinical characteristics between patients with and without sonographic diagnosis of uterine leiomyoma

  Demographic and clinical data     Uterine leiomyoma at ultrasound   *P*-value   
  --------------------------------- --------------------------------- ----------- ----------
  Age (years)                                                                     
   19 or less                       100.0%                            0.0%        0.0001
   20--39                           89.0%                             11.0%       
   40--59                           54.6%                             45.4%       
   60 or more                       80.5%                             19.5%       
  Education                                                                       
   High school or less              72.6%                             27.4%       0.134
   College or more                  77.0%                             23.0%       
  Marital status                                                                  
   Married                          69.2%                             30.8%       \<0.0001
   Other                            83.9%                             16.1%       
  Body mass index                                                                 
   18.4 or less                     85.7%                             14.3%       0.002
   18.5--24.9                       79.2%                             20.8%       
   25--29.9                         66.9%                             33.1%       
   30--34.9                         62.3%                             37.7%       
   35 or more                       54.5%                             45.5%       
  Age at menarch (years)                                                          
   12 or less                       74.0%                             26.0%       0.500
   13 or more                       74.4%                             25.6%       
  Pregnancy                                                                       
   No                               89.4%                             10.6%       \<0.0001
   Yes                              67.1%                             32.9%       
  Number of pregnancies                                                           
   1                                65.4%                             34.6%       0.741
   2                                69.3%                             30.7%       
   3 or more                        66.4%                             33.6%       
  Delivery                                                                        
   No                               87.4%                             12.6%       \<0.0001
   Yes                              66.8%                             33.2%       
  Number of deliveries                                                            
   1                                63.2%                             36.8%       0.120
   2 or more                        69.3%                             30.7%       
  Miscarriage                                                                     
   No                               68.6%                             33.7%       0.143
   Yes                              62.0%                             38.0%       
  Cesarean section (401 women)                                                    
   No one                           66.3%                             33.7%       0.360
   One or more                      69.2%                             30.8%       
  Contraception                                                                   
   Combined pill                    85.9%                             14.1%       \<0.0001
   Progestin pill or hormonal IUD   70.4%                             29.6%       
   Other                            69.6%                             30.4%       
  Menopause                                                                       
   No                               76.1%                             23.9%       0.011
   Yes                              64.4%                             35.6%       
  Presenting symptom                                                              
   Menorrhagia                      26.7%                             73.3%       \<0.0001
   Metrorrhagia                     63.2%                             36.8%       
   Pelvic pain                      64.3%                             35.7%       
   Other                            78.8%                             21.2%       

**Abbreviation:** IUD, intrauterine device.

###### 

Presenting symptoms according to number of uterine leiomyomas at ultrasound

  Presenting symptom   Uterine leiomyomas at ultrasound   *P*-value   
  -------------------- ---------------------------------- ----------- -------
  Metrorrhagia         72.0%                              28.0%       0.018
  Menorrhagia          72.7%                              27.3%       
  Pelvic pain          55.0%                              45.0%       
  Other                41.9%                              58.1%       

###### 

Presenting symptoms according to size of largest uterine leiomyoma at ultrasound

  Presenting symptom   Size of largest uterine leiomyoma   *P*-value   
  -------------------- ----------------------------------- ----------- -------
  Metrorrhagia         60.0%                               40.0%       0.215
  Menorrhagia          72.7%                               27.3%       
  Pelvic pain          75.0%                               25.0%       
  Other                80.0%                               20.0%       
